A5046706472- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Lipoproteins and Cardiovascular Health
- Cardiac electrophysiology and arrhythmias
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Imaging and Diagnostics
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cardiac Fibrosis and Remodeling
- Peripheral Artery Disease Management
- Acute Ischemic Stroke Management
- Cardiac Health and Mental Health
- Adipokines, Inflammation, and Metabolic Diseases
- Coronary Interventions and Diagnostics
- Venous Thromboembolism Diagnosis and Management
- Cardiovascular and exercise physiology
- Pharmaceutical Economics and Policy
- Acute Myocardial Infarction Research
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac pacing and defibrillation studies
- Dementia and Cognitive Impairment Research
- Diabetes Treatment and Management
Riga Stradiņš University
2014-2021
Riga East University Hospital
2014-2021
Faculty (United Kingdom)
2021
Latvian Biomedical Research and Study Centre
2014
Kontext: U pacientů s fibrilací síní se k obnově sinusového rytmu běžně provádí elektrická kardioverze. Dlouhodobé hodnoty incidence klinických příhod a udržení po elektrické kardioverzi však nejsou přesně známy. Tato monocentrická studie zkoumala jednoroční incidenci rizikové faktory vzniku kardiovaskulárních recidivy fibrilace síní.Metody: Do prospektivní bylo zařazeno 188 síní, u nichž byla provedena V následném jednoročním sledování, jehož zúčastnili pacienti jejich praktičtí lékaři,...
Abstract Atrial fibrillation (AF) conversion to sinus rhythm by electrical cardioversion (ECV) is followed the challenge of preventing arrhythmia recurrence, especially in high-risk patients. The properties class IC, III and also II antiarrhythmic medications have been established, but not all effects studied. aim study was compare efficacy IC medications, additionally medication with a mechanism action, or taken concomitantly beta-blocker, for post-cardioversion maintenance patients AF. A...
Introduction: The most important factor for efficacy and safety patients with atrial fibrillation (AF) undergoing electrical cardioversion (ECV) is appropriate use of oral anticoagulant (OAC) therapy. Dabigatran a possible alternative OAC therapy before after ECV versus warfarin. Methods: We have analysed the data collected before, during in 1046 (pts) ECV. All pts had AF, 885 defined as persistent 161 long-acting, mean CHA2DS2 VASc score was 3.1 ± 1.8, 735 one or two anamnesis. 628 (60%)...
Abstract Patients with atrial fibrillation are faced an increased risk of thromboembolic events, myocardial infarction, chronic heart failure and death. For some patients fibrillation, direct current cardioversion (DCCV) is a strategy that can be used to reacquire sinus rhythm. Our aim was analyse the most commonly medications after electrical cardioversion, reasons for not using them, effects pharmacotherapy on recurrence rates, compare results data from studies in 2014. The prospective...
Background: Recurrence prevention after Atrial Fibrillation (AF) termination by Eelectrical Cardioversion (ECV) remains challenging. Increasing attention is paid to pathophysiological effects of non-Antiarrhythmic Drugs (non-AADs), nevertheless, with heterogeneous results. Objective: We evaluated the potential benefits different non-AADs as adjunctive therapy Antiarrhythmic (AADs) for AF recurrence sinus rhythm restoration ECV in high-risk patients. Methods: The study was conducted among...